Clinical and microbiologic outcomes of quinolone prophylaxis in children with acute myeloid leukemia

Pediatric Infectious Disease Journal

Volumn 34, Issue 4, 2015, Pages e78-e84

  Felsenstein, Susanna ^a   Orgel, Etan ^b   Rushing, Teresa ^a   Fu, Cecilia ^b   Hoffman, Jill A ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

acute myeloid leukemia; immunocompromised host; infections

Indexed keywords

AMINOGLYCOSIDE; CIPROFLOXACIN; CLOFARABINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; MEROPENEM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ALLERGIC RASH; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; FEVER; HUMAN; INFECTION PREVENTION; MALE; MORTALITY; NEUTROPENIA; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE MEMORY; ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; BACTERIUM; CLASSIFICATION; COMPLICATION; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; PRESCHOOL CHILD; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; BACTERIA; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, MYELOID, ACUTE; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84937560271     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000591     Document Type: Article

References (51)

1. Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. Br J Haematol. 2012;159:259-276.
2. Lehrnbecher T, Ethier MC, Creutzig U, et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukemia. Br J Haematol. 2009;147:125-128
3. Sung L, Lange BJ, Gerbing RB, et al. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007;110:3532-3539.
4. Gafter-Gvili A, Fraser A, Paul M, et al. Cochrane Database Syst Rev. 2012;1:CD004386
5. Bucaneve G, Micozzi A, Menichetti F, et al. Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) infection program. N Engl J Med. 2005;353:977-987
6. Flowers CR, Seidenfeld J, Bow EJ, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31:794-810.
7. Sung L, Aplenc R, Alonzo TA, et al. Effectiveness of supportive care measures to reduce infections in pediatric AML: A report from the Children's Oncology Group. Blood. 2013;121:3573-3577.
8. Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis. 2007;45:1296-1304.
9. Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008;113:376-382.
10. Sung L, Aplenc R, Zaoutis T, et al. Infections in pediatric acute myeloid leukemia: lessons learned and unresolved questions. Pediatr Blood Cancer. 2008;51:458-460.
11. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-e93.
12. Wisplinghoff H, Seifert H, Tallent SM, et al. Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr Infect Dis J. 2003;22:686-691.
13. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-1821.
14. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: Analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004;18:72-77.
15. Castagnola E, Rossi MR, Cesaro S, et al. Incidence of bacteremias and invasive mycoses in children with acute non-lymphoblastic leukemia: results from a multi-center Italian study. Pediatr Blood Cancer. 2010;55:1103-1107.
16. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatmentrelated mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AMLBFM 98. J Clin Oncol. 2004;22:4384-4393.
17. Cullen M, Steven N, Billingham L, et al. Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/-Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988-998.
18. Sung L, Phillips R, Lehrnbecher T. Time for paediatric febrile neutropenia guidelines-children are not little adults. Eur J Cancer. 2011;47:811-813.
19. Castagnola E, Boni L, Giacchino M, et al. Infectious Diseases Study Group of the Italian Association of Pediatric Hematology and Oncology. A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. Pediatr Infect Dis J. 2003;22:359-365.
20. Yousef AA, Fryer CJ, Chedid FD, et al. A pilot study of prophylactic ciprofloxacin during delayed intensification in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004;43:637-643.
21. Johannsen KH, Handrup MM, Lausen B, et al. High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine. Pediatr Blood Cancer. 2013;60:1154-1160.
22. Crozier F. Pneumocystis carinii pneumonia prophylaxis: current therapies and recommendations. J Pediatr Oncol Nurs. 2011;28:179-184.
23. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol. 1997;99:580-588.
24. Sahasrabhojane P, Galloway-Peña J, Velazquez L, et al. Species-level assessment of the molecular basis of fluoroquinolone resistance among viridans group streptococci causing bacteraemia in cancer patients. Int J Antimicrob Agents. 2014;43:558-562.
25. Gamis AS, Howells WB, DeSwarte-Wallace J, et al. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: A report from the Children's cancer group study CCG-2891. J Clin Oncol. 2000;18:1845-1855.
26. Sung L, Gamis A, Alonzo TA, et al. Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer. 2009;115:1100-1108.
27. Chong Y, Yakushiji H, Ito Y, et al. Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis. 2011;15:e277-e281.
28. Blijlevens NM, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: An overview. Bone Marrow Transplant. 2000;25:1269-1278.
29. Wisplinghoff H, Reinert RR, Cornely O, et al. Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. J Clin Microbiol. 1999;37:1876-1880.
30. Husain E, Whitehead S, Castell A, et al. Viridans streptococci bacteremia in children with malignancy: relevance of species identification and penicillin susceptibility. Pediatr Infect Dis J. 2005;24:563-566.
31. van Vliet MJ, Tissing WJ, Dun CA, et al. Chemotherapy treatment in pediatric patients with acute myeloid leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization with potentially pathogenic bacteria in the gut. Clin Infect Dis. 2009;49:262-270.
32. Sixou JL, De Medeiros-Batista O, Gandemer V, et al. The effect of chemotherapy on the supragingival plaque of pediatric cancer patients. Oral Oncol. 1998;34:476-483.
33. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev. 2007;20:133-163.
34. Inaba H, Gaur AH, Cao X et al. Feasibility, efficacy, and diverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. Cancer 2014;120:1985-1992
35. Gassas A, Grant R, Richardson S, et al. Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients. J Clin Oncol. 2004;22:1222-1227.
36. Sung L, Manji A, Beyene J, et al. Fluoroquinolones in children with fever and neutropenia: A systematic review of prospective trials. Pediatr Infect Dis J. 2012;31:431-435.
37. Okamoto Y, Ribeiro RC, Srivastava DK, et al. Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia. J Pediatr Hematol Oncol. 2003;25:696-703.
38. Martino R, Subira M, Manteiga R, et al. Viridans streptococcal bacteremia and viridans streptococcal shock syndrome in neutropenic patients: comparison between children and adults receiving chemotherapy or undergoing bone marrow transplantation. Clin Infect Dis. 1995;20:476-477.
39. Bruckner L, Gigliotti F. Viridans group streptococcal infections among children with cancer and the importance of emerging antibiotic resistance. Semin Pediatr Infect Dis. 2006;17:153-160.
40. Brunet AS, Ploton C, Galambrun C, et al. Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2006;47:765-772.
41. Kern W, Kurrle E, Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection. 1990;18:138-145.
42. De Pauw BE, Donnelly JP, De Witte T, et al. Options and limitations of long-Term oral ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients. Bone Marrow Transplant. 1990;5:179-182.
43. Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol. 2007;5(9 suppl 4):3-11.
44. Classen DC, Burke JP, Ford CD, et al. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med. 1990;89:441-446.
45. Ng ES, Liew Y, Earnest A, et al. Audit of fluoroquinolone prophylaxis against chemotherapy-induced febrile neutropenia in a hospital with highly prevalent fluoroquinolone resistance. Leuk Lymphoma. 2011;52:131-133.
46. Castagnola E, Haupt R, Micozzi A, et al. Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres. Clin Microbiol Infect. 2005;11:505-507.
47. Miedema KG, Winter RH, Ammann RA, et al. Bacteria causing bacteremia in pediatric cancer patients presenting with febrile neutropenia-species distribution and susceptibility patterns. Support Care Cancer. 2013;21:2417-2426.
48. Ito JI, Tegtmeier BR, O'Donnell MR. Antibacterial prophylaxis in patients with cancer and neutropenia. N Engl J Med. 2006;354:90-4; author reply 90.
49. Rangaraj G, Granwehr BP, Jiang Y, et al. Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer. 2010;116:967-973.
50. Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis. 2005;40:1087-1093.
51. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24:111-118.